Finerenone reduces CKD progression, CV risk
11 Dec 2020
bởiRoshini Claire Anthony
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.
Finerenone reduces CKD progression, CV risk
11 Dec 2020
